2017
Primary melanoma histologic subtype (HS) impacts melanoma specific survival (MSS) and response to systemic therapy.
Lattanzi M, Lee Y, Robinson E, Weiss S, Moran U, Simpson D, Shapiro R, Berman R, Pavlick A, Wilson M, Kirchhoff T, Zhong J, Osman I. Primary melanoma histologic subtype (HS) impacts melanoma specific survival (MSS) and response to systemic therapy. Journal Of Clinical Oncology 2017, 35: 9577-9577. DOI: 10.1200/jco.2017.35.15_suppl.9577.Peer-Reviewed Original ResearchMelanoma-specific survivalWorse melanoma-specific survivalHistologic subtypeNodular melanomaNYU cohortSEER cohortMetastatic settingSystemic therapyPrimary histologic subtypeCheckpoint inhibitor immunotherapyMultivariate Cox modelThick primary tumorsDifferent clinical behaviorPrimary nodular melanomaNext-generation sequencingSignificant predictorsClinical Trial ReportingLow mutational burdenMutational landscapeHigh mitotic indexSpecific survivalWorse prognosisClinical behaviorPrimary tumorMelanoma survival
2016
Impact of aging on host immune response and survival in melanoma: an analysis of 3 patient cohorts
Weiss SA, Han J, Darvishian F, Tchack J, Han SW, Malecek K, Krogsgaard M, Osman I, Zhong J. Impact of aging on host immune response and survival in melanoma: an analysis of 3 patient cohorts. Journal Of Translational Medicine 2016, 14: 299. PMID: 27760559, PMCID: PMC5070187, DOI: 10.1186/s12967-016-1026-2.Peer-Reviewed Original ResearchConceptsMelanoma-specific survivalShorter melanoma-specific survivalHost immune responseImmune responseTCGA cohortAge groupsClinicopathologic featuresSurvival outcomesPatient cohortPrimary melanomaHost anti-tumor immune responseMelanoma diagnosisAnti-tumor immune responseMelanoma Cooperative GroupIndependent prognostic factorPopulation-based surveillanceEnd Results ProgramGreater prognostic impactMelanoma patient cohortTop upstream regulatorsYounger age groupsAge-related factorsBrisk TILsConclusionsOlder ageLymphocyte measurements